Dr E. Keith Borden: Inaugural president of the Canadian Association for Population Therapeutics
Main Article Content
Keywords
Borden
Abstract
Dr E. Keith Borden passed away in Simcoe, Ontario, on July 17, 2019 at the age of 87.1 He played a foundational role in the establishment of the Canadian Association for Population Therapeutics (CAPT).
References
1. Dr. E Keith Borden. Simcoe Reformer, July 19, 2019. https://simcoereformer.remembering.ca/obituary/dr-e-keith-borden-1075783118.
2. Borden EK, Lee JG. A methodologic study of post-marketing drug evaluation using a pharmacy-based approach. J Chronic Dis 1982;35:803–16.
3. Rawson NSB. Drug safety: problems, pitfalls and solutions in identifying and evaluating risk. Victoria: Friesen Press, 2016.
4. Gardner JS, Baker MI, Borden EK. Postmarketing surveillance in Canadian pharmacies. Can Pharmaceut J 1984;117:57–9.
5. Willison D, Gaebel KA, Borden EK, et al. Experience in the development of a postmarketing surveillance network: the Pharmacy Medication Monitoring Program. Ann Pharmacother 1995;29:1208–13.
6. Borden EK, Gardner JS, Westland MM, Gardner SD. Postmarketing drug surveillance. JAMA 1984;251:729.
7. West R, Borden EK, Collet JP, Rawson NSB, Tonks RS. “Cost-effectiveness” estimates result in flawed decision-making in listing drugs for reimbursement. Can J Public Health 2002;93:421–5.
8. West R, Borden EK, Collet JP, Rawson NSB, Tonks RS. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces. Can J Clin Pharmacol 2003;10:207–10.
9. Borden EK. Post-marketing surveillance: drug epidemiology. J Int Med Res 1981;9:401-7.
10. The Belmont Report. Rockville, MD: Office for Human Research Protections, 2018. https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html.
2. Borden EK, Lee JG. A methodologic study of post-marketing drug evaluation using a pharmacy-based approach. J Chronic Dis 1982;35:803–16.
3. Rawson NSB. Drug safety: problems, pitfalls and solutions in identifying and evaluating risk. Victoria: Friesen Press, 2016.
4. Gardner JS, Baker MI, Borden EK. Postmarketing surveillance in Canadian pharmacies. Can Pharmaceut J 1984;117:57–9.
5. Willison D, Gaebel KA, Borden EK, et al. Experience in the development of a postmarketing surveillance network: the Pharmacy Medication Monitoring Program. Ann Pharmacother 1995;29:1208–13.
6. Borden EK, Gardner JS, Westland MM, Gardner SD. Postmarketing drug surveillance. JAMA 1984;251:729.
7. West R, Borden EK, Collet JP, Rawson NSB, Tonks RS. “Cost-effectiveness” estimates result in flawed decision-making in listing drugs for reimbursement. Can J Public Health 2002;93:421–5.
8. West R, Borden EK, Collet JP, Rawson NSB, Tonks RS. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces. Can J Clin Pharmacol 2003;10:207–10.
9. Borden EK. Post-marketing surveillance: drug epidemiology. J Int Med Res 1981;9:401-7.
10. The Belmont Report. Rockville, MD: Office for Human Research Protections, 2018. https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html.
Article Sidebar
Published
Dec 6, 2019
Article Details
How to Cite
Rawson, N. S. B., & West, R. (2019). Dr E. Keith Borden: Inaugural president of the Canadian Association for Population Therapeutics. Journal of Population Therapeutics and Clinical Pharmacology, 26(4), e29-e31. https://doi.org/10.15586/jptcp.v26i4.656
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.